Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

Tumor markers are becoming increasingly important in breast cancer research because of their impact on prognosis, treatment, and survival, and because of their relation to breast cancer subtypes. The triple‐negative phenotype is important because of its relation to the basal‐like subtype of breast cancer.

[1]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[2]  J. Benítez,et al.  Prognostic Significance of Basal-Like Phenotype and Fascin Expression in Node-Negative Invasive Breast Carcinomas , 2006, Clinical Cancer Research.

[3]  N. Gordon.  Socioeconomic factors and breast cancer in black and white Americans , 2003, Cancer and Metastasis Reviews.

[4]  V. Shavers,et al.  Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35 , 2003, Cancer.

[5]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[6]  William D. Foulkes,et al.  Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .

[7]  Zhao Chen,et al.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.

[8]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[9]  P. Levine,et al.  Histologic grade, stage, and survival in breast carcinoma , 2003, Cancer.

[10]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  O. Olopade,et al.  Breast Cancer and Race: A Rising Tide Does Not Lift All Boats Equally , 2005, Perspectives in biology and medicine.

[12]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[13]  B. Wójcik,et al.  Breast carcinoma survival analysis for african american and white women in an equal‐access health care system , 1998, Cancer.

[14]  L. Newman,et al.  Breast cancer in African-American women. , 2005, The oncologist.

[15]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD, , 2006 .

[16]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[17]  G. Colditz,et al.  Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Newman,et al.  Age-related differences in breast cancer stage at diagnosis between black and white patients in an urban community hospital , 1997, Annals of Surgical Oncology.

[19]  N. Breen,et al.  The relationship of socio-economic status and access to minimum expected therapy among female breast cancer patients in the National Cancer Institute Black-White Cancer Survival Study. , 1999, Ethnicity & disease.

[20]  Chyke A Doubeni,et al.  Disparities and survival among breast cancer patients. , 2005, Journal of the National Cancer Institute. Monographs.

[21]  C. Perou,et al.  Race and the poor prognosis basal breast tumor (BBT) phenotype in the population-based Carolina Breast Cancer Study (CBCS). , 2004, Journal of Clinical Oncology.

[22]  G. Colditz,et al.  African‐American ethnicity, socioeconomic status, and breast cancer survival , 2002, Cancer.

[23]  L. Bégin,et al.  Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.

[24]  J Z Ayanian,et al.  The relation between health insurance coverage and clinical outcomes among women with breast cancer. , 1994, The New England journal of medicine.

[25]  Cathy J Bradley,et al.  Race, socioeconomic status, and breast cancer treatment and survival. , 2002, Journal of the National Cancer Institute.

[26]  April Fritz,et al.  International Classification of Diseases for Oncology: ICD-0. , 2000 .

[27]  M. West,et al.  Racial differences in breast carcinoma survival , 2000, Cancer.

[28]  S. Schnitt,et al.  Prevalence of BRCA1 mutations in triple negative breast cancer (BC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  W. McWhorter,et al.  Black/white differences in type of initial breast cancer treatment and implications for survival. , 1987, American journal of public health.

[31]  J. Cunningham,et al.  Racial disparities in female breast cancer in South Carolina: clinical evidence for a biological basis , 2004, Breast Cancer Research and Treatment.

[32]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[33]  H. Becher,et al.  Widening disparity in survival between white and African‐American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system , 2003, Cancer.

[34]  R. Millikan,et al.  Tumor characteristics in African American and white women , 2001, Breast Cancer Research and Treatment.

[35]  W. Wright,et al.  Socioeconomic status and breast cancer incidence in California for different race/ethnic groups , 2001, Cancer Causes & Control.

[36]  J. Fleiss,et al.  Statistical methods for rates and proportions , 1973 .

[37]  H. Freeman,et al.  Racial disparities in breast carcinoma survival rates , 2003, Cancer.

[38]  C. Howe,et al.  African‐American/White differences in breast carcinoma , 2004, Cancer.

[39]  M. Rotman,et al.  Early onset of breast carcinoma in African American women with poor prognostic factors. , 1999, American journal of clinical oncology.